

EXHIBIT B

 COPY

ORIGINAL FILED

DEC 05 2006

LOS ANGELES
SUPERIOR COURT

1 Michael K. Brown (CSBN 104252)
2 Thomas J. Yoo (CSBN 175118)
3 REED SMITH LLP
355 South Grand Avenue, Suite 2900
4 Los Angeles, CA 90071
Telephone: (213) 457-8000
Facsimile: (213) 457-8080

5 Steven J. Boranian (CSBN 174183)
6 Kevin M. Hara (CSBN 221604)
7 REED SMITH LLP
Two Embarcadero Center, Suite 2000
8 San Francisco, CA 94111
Telephone: (415) 543-8700
Facsimile: (415) 391-8269

9 Attorneys for Defendant
10 Merck & Co., Inc.

11 SUPERIOR COURT OF CALIFORNIA
12 FOR THE COUNTY OF LOS ANGELES

13
14 COORDINATION PROCEEDING
15 SPECIAL TITLE [Rule 1550(b)]

16 IN RE VIOXX® CASES

17 GENEVA STYLES and JOHN STYLES,

18 Plaintiffs,

19 vs.

20 MERCK & COMPANY, INC., a
21 corporation; MCKESSON
22 CORPORATION, a corporation;
23 AMERISOURCEBERGEN
24 CORPORATION, a corporation; PFIZER
25 INC.; PHARMACIA CORPORATION; G.
D. SEARLE LLC, (FKA G. D. SEARLE &
CO.); DOES 1 to 100;
26 PHARMACEUTICAL DEFENDANT
27 DOES 101 to 200; DISTRIBUTOR
28 DEFENDANT DOES 201 to 300,
inclusive,

Defendants,

CASE NO.: JCCP 4247

Case No.: BC359104

DEFENDANT MERCK & CO., INC.'S
ANSWER TO PLAINTIFFS' UNVERIFIED
COMPLAINT AND REQUEST FOR JURY
TRIAL

DEFENDANT MERCK & CO., INC.'S ANSWER TO PLAINTIFFS' UNVERIFIED COMPLAINT AND
REQUEST FOR JURY TRIAL

REED SMITH LLP
Attorneys for Defendant Merck & Co., Inc.

1 Michael K. Brown (CSBN 104252)
2 Thomas J. Yoo (CSBN 175118)
3 REED SMITH LLP
355 South Grand Avenue, Suite 2900
4 Los Angeles, CA 90071
Telephone: (213) 457-8000
Facsimile: (213) 457-8080

5 Steven J. Boranian (CSBN 174183)
6 Kevin M. Hara (CSBN 221604)
7 REED SMITH LLP
Two Embarcadero Center, Suite 2000
8 San Francisco, CA 94111
Telephone: (415) 543-8700
Facsimile: (415) 391-8269

9 Attorneys for Defendant
10 Merck & Co., Inc.

11 SUPERIOR COURT OF CALIFORNIA
12 FOR THE COUNTY OF LOS ANGELES
13

14 COORDINATION PROCEEDING
15 SPECIAL TITLE [Rule 1550(b)]

16 IN RE VIOXX® CASES

17 GENEVA STYLES and JOHN STYLES,

18 Plaintiffs,

19 vs.

20 MERCK & COMPANY, INC., a
21 corporation; MCKESSON
22 CORPORATION, a corporation;
23 AMERISOURCEBERGEN
24 CORPORATION, a corporation; PFIZER
25 INC.; PHARMACIA CORPORATION; G.
D. SEARLE LLC, (FKA G. D. SEARLE &
CO.); DOES 1 to 100;
26 PHARMACEUTICAL DEFENDANT
27 DOES 101 to 200; DISTRIBUTOR
28 DEFENDANT DOES 201 to 300,
inclusive,

Defendants,

CASE NO.: JCCP 4247

Case No.: BC359104

**DEFENDANT MERCK & CO., INC.'S
ANSWER TO PLAINTIFFS' UNVERIFIED
COMPLAINT AND REQUEST FOR JURY
TRIAL**

REED SMITH LLP
A limited liability partnership formed in the State of Delaware

GENERAL DENIAL

1
2
3 1. Answering plaintiffs' unverified Complaint, defendant Merck & Co., Inc.,
4 ("answering defendant") generally and specifically denies every allegation of the Complaint, and
5 the whole thereof, and denies that plaintiffs were injured or damaged in any sum, or at all, by
6 reason of any act or omission of answering defendant or anyone acting on its behalf.
7

AFFIRMATIVE DEFENSES

8
9
10 2. As a first affirmative defense, answering defendant alleges that the Complaint fails
11 to state facts sufficient to constitute a cause of action against this answering defendant.
12

13 3. As a second affirmative defense, answering defendant alleges that this Court lacks
14 personal jurisdiction over answering defendant.
15

16 4. As a third affirmative defense, answering defendant alleges that California's
17 judicially-created definitions of manufacturing defect and design defect, and standards for
18 determining whether there has been an actionable failure to warn, are unconstitutional in that,
19 among other things, they are void for vagueness and an undue burden on interstate commerce, as
20 well as an impermissible effort to regulate in an area that previously has been preempted by the
21 federal government.
22

23 5. As a fourth affirmative defense, answering defendant alleges that to the extent that
24 plaintiffs assert claims based on answering defendant's alleged adherence or lack of adherence to
25 and compliance with applicable federal laws, regulations, and rules, such claims are preempted by
26 federal law under the Supremacy Clause of the United States Constitution.
27
28

1 6. As a fifth affirmative defense, answering defendant alleges that plaintiffs may have
2 failed to exercise reasonable care to mitigate their alleged damages.

3
4 7. As a sixth affirmative defense, answering defendant alleges that the provisions of
5 California Civil Code Section 1431.2 are applicable to the Complaint and each cause of action
6 therein.

7
8 8. As a seventh affirmative defense, answering defendant alleges that plaintiffs'
9 claims are barred in whole or in part by the applicable statutes of limitations, including but not
10 limited to California Code of Civil Procedure Sections 335.1 and 338 and former section 340(3),
11 California Business and Professions Code Section 17208, and California Civil Code Section
12 1783.

13
14 9. As an eighth affirmative defense, answering defendant alleges that the subject
15 pharmaceutical product manufactured or distributed by answering defendant has at all relevant
16 times been available only upon the prescription of a licensed physician, and plaintiffs' prescribing
17 physicians stood in the position of the learned intermediaries between answering defendant and
18 plaintiff. To the extent that plaintiffs assert claims based on an alleged failure by answering
19 defendant to warn plaintiffs directly of alleged dangers associated with the use of the subject
20 pharmaceutical product manufactured or distributed by answering defendant, such claims are
21 barred because answering defendant has discharged its duty to warn in its warnings to the
22 prescribing physicians, under the learned intermediary doctrine.

23
24 10. As a ninth affirmative defense, answering defendant alleges that plaintiffs' claims
25 are barred in whole or in part because the subject pharmaceutical product manufactured or
26 distributed by answering defendant is a prescription medication which is "unavoidably unsafe"
27 within the meaning of Comment k to Section 402A of the Restatement (Second) of Torts.
28

REED SMITH LLP
A limited liability partnership formed in the State of Delaware

11. As a tenth affirmative defense, answering defendant alleges that plaintiffs' claims are barred in whole or in part because answering defendant provided adequate "direction or warnings" as to the use of the subject pharmaceutical product manufactured or distributed by answering defendant within the meaning of Comment j to Section 402A of the Restatement (Second) of Torts.

12. As an eleventh affirmative defense, answering defendant alleges that plaintiffs' claims are barred in whole or in part because the subject pharmaceutical product manufactured or distributed by answering defendant "provides net benefits for a class of patients" within the meaning of Comment f to Section 6 of the Restatement (Third) of Torts: Products Liability.

13. As a twelfth affirmative defense, answering defendant alleges that the subject pharmaceutical product manufactured or distributed by answering defendant, and the design, manufacture, and promotion thereof, conformed to the state-of-the-art for the design, manufacture, and promotion of such, or similar products based on available medical and scientific knowledge.

14. As a thirteenth affirmative defense, answering defendant alleges that plaintiffs' claims are barred in whole or in part under the applicable state law because subject pharmaceutical product manufactured or distributed by answering defendant was subject to and received pre-market approval by the Food and Drug Administration under 52 Stat. 1040, 21 U.S.C. § 301.

15. As a fourteenth affirmative defense, answering defendant alleges that plaintiffs' claims are barred in whole or in part by the deference given to the primary jurisdiction of the Food and Drug Administration over the subject pharmaceutical product manufactured or distributed by answering defendant under applicable federal laws, regulations, and rules.

1 16. As a fifteenth affirmative defense, answering defendant alleges that the subject
2 pharmaceutical product manufactured or distributed by answering defendant complied with the
3 applicable laws, regulations, and rules promulgated and enforced by the Food and Drug
4 Administration. Compliance with such laws, regulations, and rules demonstrates that due care
5 and reasonable prudence were exercised in the design, manufacture, and promotion of the subject
6 pharmaceutical product and that the subject pharmaceutical product was not defective in any
7 respect.

8
9 17. As a sixteenth affirmative defense to each cause of action in the Complaint,
10 answering defendant alleges that plaintiffs' claims are barred in whole or in part because there is
11 no private right of action concerning matters regulated by the Food and Drug Administration
12 under applicable federal laws, regulations, and rules.

13
14 18. As a seventeenth affirmative defense, answering defendant alleges that if plaintiffs
15 have sustained injury or loss as alleged in the Complaint, such injury or loss was only so
16 sustained after plaintiff knowingly and voluntarily assumed the risk of any injury as the result of
17 the consumption of, administration of, or exposure to any drug or pharmaceutical preparation
18 manufactured or distributed by answering defendant and prescribed by the plaintiff's physicians.

19
20 19. As an eighteenth affirmative defense, answering defendant alleges that if plaintiffs
21 have sustained injury or loss as alleged in the Complaint, such injury or loss may have been
22 directly and proximately caused by the operation of nature or the intervening or superseding acts
23 of persons not having real or apparent authority to take said actions on behalf of answering
24 defendant, over whom answering defendant had no control, and/or for whom answering
25 defendant may not be held accountable.

20. As a nineteenth affirmative defense, answering defendant alleges that plaintiffs may have been careless and negligent in the matters alleged, thereby causing and contributing to any alleged injury, damage, or loss to plaintiffs.

21. As a twentieth affirmative defense, answering defendant alleges that if plaintiffs have sustained injury or loss as alleged in the Complaint, such injury or loss may have been caused by parties other than answering defendant, or third persons not parties to this action, who may have been negligent, legally responsible, or otherwise at fault. In the event of a finding of liability in favor of plaintiffs, a settlement, or a judgment against answering defendant, answering defendant requests an apportionment of fault among all parties and third persons as permitted by *Li v. Yellow Cab Company* and *America Motorcycle Association v. Superior Court*. Answering defendant also requests a judgment and declaration of partial indemnification and contribution against all other parties or third persons in accordance with the apportionment of fault.

22. As a twenty-first affirmative defense, answering defendant alleges that if plaintiffs have sustained injury or loss as alleged in the Complaint, such injury or loss resulted from pre-existing and/or unrelated medical, genetic, and/or environmental conditions, diseases or illnesses, subsequent medical conditions, idiosyncratic reactions, or natural course of conditions for which answering defendant is not responsible.

23. As a twenty-second affirmative defense, answering defendant alleges that plaintiffs' claims are barred under Section 4, et seq., of the Restatement (Third) of Torts: Products Liability.

24. As a twenty-third affirmative defense, answering defendant alleges that if plaintiffs have sustained injury or loss as alleged in the Complaint, such injury or loss may have been proximately caused by plaintiff's misuse or abuse of subject pharmaceutical product manufactured or distributed by answering defendant.

1 25. As a twenty-fourth affirmative defense, answering defendant alleges that plaintiffs'
2 claims are barred in whole or in part by the First Amendment of the United States Constitution
3 and similar provisions in the Constitution of the State of California which protect, among other
4 things, answering defendant's right to promote and advertise the subject pharmaceutical product.

5
6 26. As a twenty-fifth affirmative defense, answering defendant alleges that plaintiffs'
7 claims are barred in whole or in part by the doctrines of accord and satisfaction, good faith,
8 consent, res judicata, payment and release, waiver, collateral estoppel, judicial estoppel, equitable
9 estoppel, unclean hands, and/or laches.

10
11 27. As a twenty-sixth affirmative defense, answering defendant alleges that plaintiffs'
12 claims are barred in whole or in part because all acts or omissions by answering defendant (or its
13 agent or representative) were privileged or justified and any claim based thereon is barred.

14
15 28. As a twenty-seventh affirmative defense, answering defendant alleges that
16 plaintiffs' claims are barred in whole or in part because plaintiffs lack standing to bring such
17 claims.

18
19 29. As a twenty-eighth affirmative defense, answering defendant alleges that plaintiffs'
20 claims are barred in whole or in part because the Complaint fails to join necessary and
21 indispensable parties.

22
23 30. As a twenty-ninth affirmative defense, answering defendant alleges that plaintiffs'
24 claims are barred in whole or in part because they have been improperly joined in this action.

25
26 31. As a thirtieth affirmative defense, answering defendant alleges that plaintiffs'
27 claims are barred in whole or in part because they have been filed in an improper venue.

28

1 32. As a thirty-first affirmative defense, answering defendant alleges that to the extent
2 plaintiffs are seeking recovery for benefits entitled to be received or actually received from any
3 other source for injuries alleged in the Complaint, such benefits are not recoverable in this action.

4
5 33. As a thirty-second affirmative defense, answering defendant alleges that to the
6 extent that plaintiffs seek punitive damages for the conduct which allegedly caused injuries
7 asserted in the Complaint, punitive damages are barred or reduced by applicable law or statute or,
8 in the alternative, are unconstitutional insofar as they violate the due process protections afforded
9 by the United States Constitution, the excessive fines clause of the Eighth Amendment of the
10 United States Constitution, the Commerce Clause of the United States Constitution, the Full Faith
11 and Credit Clause of the United States Constitution, and applicable provisions of the Constitution
12 of the State of California. Any law, statute, or other authority purporting to permit the recovery
13 of punitive damages in this case is unconstitutional, facially and as applied, to the extent that,
14 without limitation, it: (1) lacks constitutionally sufficient standards to guide and restrain the jury's
15 discretion in determining whether to award punitive damages and/or the amount, if any; (2) is
16 void for vagueness in that it failed to provide adequate advance notice as to what conduct will
17 result in punitive damages; (3) unconstitutionally may permit recovery of punitive damages based
18 on out-of-state conduct, conduct that complied with applicable law, or conduct that was not
19 directed, or did not proximately cause harm, to plaintiffs; (4) unconstitutionally may permit
20 recovery of punitive damages in an amount that is not both reasonable and proportionate to the
21 amount of harm, if any, to plaintiff and to the amount of compensatory damages, if any; (5)
22 unconstitutionally may permit jury consideration of net worth or other financial information
23 relating to answering defendant; (6) lacks constitutionally sufficient standards to be applied by the
24 trial court in post-verdict review of any punitive damages award; (7) lacks constitutionally
25 sufficient standards for appellate review of punitive damages awards; and (8) otherwise fails to
26 satisfy Supreme Court precedent, including, without limitation, *Pacific Mutual Life Ins. Co. v.*
27 *Haslip*, 499 U.S. 1, 111 S.Ct. 1032 (1991); *TXO Production Corp. v. Alliance Resources, Inc.*,
28

1 509 U.S. 443, 113 S.Ct. 2711 (1993); *BMW of North America, Inc. v. Gore*, 517 U.S. 559, 116
2 S.Ct. 1589 (1996); and *State Farm Ins. Co. v. Campbell*, 123 S.Ct. 1513 (2003).

3
4 34. As a thirty-third affirmative defense, answering defendant alleges that to the extent
5 that plaintiffs seek punitive damages for an alleged act or omission of answering defendant, no
6 act or omission was oppressive, fraudulent, or malicious, under California Civil Code Section
7 3294, and therefore, any award of punitive damages is barred. Any claim for punitive damages is
8 also barred under California Civil Code Section 3294(b).

9
10 35. As a thirty-fourth affirmative defense, answering defendant alleges that plaintiffs'
11 claim under Business and Professions Code Sections 17200, et seq. and 17500, et seq. are barred
12 in whole or in part because answering defendant's conduct and all activities with respect to the
13 subject pharmaceutical product manufactured or distributed by answering defendant were lawful,
14 fair, truthful, not misleading or deceptive, and were justified based on the state of medical and
15 scientific knowledge available during the relevant time period.

16
17 36. As a thirty-fifth affirmative defense, answering defendant alleges that plaintiffs'
18 claims under Business and Professions Code Sections 17200, et seq. and 17500, et seq. are barred
19 in whole or in part because all of answering defendant's activities as alleged in the Complaint
20 were in compliance with the applicable laws, regulations, and rules, and thus cannot be deemed
21 unlawful, unfair, fraudulent, deceptive, untrue, or misleading.

22
23 37. As a thirty-sixth affirmative defense, answering defendant alleges that plaintiffs'
24 claims under Business and Professions Code Sections 17200, et seq. and 17500, et seq. are barred
25 in whole or in part because plaintiffs do not qualify as private attorney general, and for that
26 reason and others, plaintiff lack standing to prosecute a claim for injunctive or monetary relief.

1 38. As a thirty-seventh affirmative defense, answering defendant alleges that plaintiffs'
2 claims under Business and Professions Code Sections 17200, et seq. and 17500, et seq. are barred
3 in whole or in part because there is no basis for injunctive relief in this action.

4
5 39. As a thirty-eighth affirmative defense, answering defendant alleges that plaintiffs'
6 claim under Business and Professions Code Sections 17200, et seq. and 17500 et seq. are barred
7 in whole or in part by the doctrine of primary jurisdiction in that the subject pharmaceutical
8 product manufactured or distributed by answering defendant and any advertisement regarding
9 such product are regulated by the Food and Drug Administration and as such, answering
10 defendant requests that this court, sitting in equity, abstain from hearing claims under Sections
11 17200 et seq. and 17500 et seq.

12
13 40. As a thirty-ninth affirmative defense, answering defendant alleges that plaintiffs are
14 not entitled to relief under Business and Professions Code Sections 17200, et seq. and 17500 et
15 seq. because plaintiff has an adequate remedy at law.

16
17 41. As a fortieth affirmative defense answering defendant alleges that plaintiffs' claims
18 under Business and Professions Code Sections 17200, et seq. and 17500 et seq. are barred in
19 whole or in part under principles of substantive and procedural due process.

20
21 42. As a forty-first affirmative defense, answering defendant alleges that to the extent
22 plaintiffs seek restitution on behalf of individuals who used the subject pharmaceutical product
23 manufactured or distributed by answering defendant and suffered no damage or loss as a result
24 thereof, restitution is unavailable as nothing has been taken from those individuals, who allegedly
25 could have an equitable basis for restitution.

26
27 43. As a forty-second affirmative defense, answering defendant alleges that plaintiffs'
28 claims for restitution for products previously used are barred in whole or in part because plaintiffs

1 or plaintiff's decedent received benefits from the subject pharmaceutical product manufactured or
2 distributed by answering defendant and nothing was wrongfully taken from such plaintiffs or
3 plaintiff's decedent.

4
5 44. As a forty-third affirmative defense, answering defendant alleges that plaintiffs'
6 claims of fraud and concealment are barred by reason of plaintiffs' failure to allege the
7 circumstances constituting the alleged fraud and concealment with particularity.

8
9 45. As a forty-fourth affirmative defense, answering defendant alleges that answering
10 defendant intends to rely upon such other affirmative defenses as may become available or
11 apparent during the course of investigation, discovery, or trial, and answering defendant reserves
12 the right to amend this Answer to assert such other defenses to which it may be entitled

13
14 WHEREFORE, answering defendant requests:


- 15
16 1. That plaintiffs take nothing by the Complaint;
17
18 2. A dismissal of the Complaint with prejudice and an award of answering
19 defendant's reasonable attorneys' fees to the extent permitted by law;
20
21 3. Judgment in favor of answering defendant and against plaintiffs;
22
23 4. Costs of suit herein; and
24
25 5. Such other and further relief that the Court may deem just and proper.
26
27
28

1 **REQUEST FOR JURY TRIAL**

2
3 Answering defendant respectfully requests a jury trial on those claims to which it is
4 entitled to a jury trial.

5
6 Dated: December 5, 2006.

REED SMITH LLP

7 

8 By

Kevin M. Hara
Attorneys for Defendant
Merck & Co., Inc.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
REED SMITH LLP
A limited liability partnership formed in the State of Delaware

PROOF OF SERVICE

I am a resident of the State of California, over the age of eighteen years, and not a party to the within action. My business address is REED SMITH LLP, 1999 Harrison Street, Suite 2400, Oakland, CA 94612-3572. On December 5, 2006, I served the following document(s) by the method indicated below:

DEFENDANT MERCK & CO., INC.'S ANSWER TO PLAINTIFF'S UNVERIFIED COMPLAINT AND REQUEST FOR JURY TRIAL

- ☐ by transmitting via facsimile on this date from fax number 510.273.8832 the document(s) listed above to the fax number(s) set forth below. The transmission was completed before 5:00 PM and was reported complete and without error.
- ☒ by placing the document(s) listed above in a sealed envelope with postage thereon fully prepaid, in the United States mail at Oakland, California addressed as set forth below. I am readily familiar with the firm's practice of collection and processing of correspondence for mailing. Under that practice, it would be deposited with the U.S. Postal Service on that same day with postage thereon fully prepaid in the ordinary course of business.
- ☐ by placing the document(s) listed above in a sealed envelope(s) and by causing personal delivery of the envelope(s) to the person(s) at the address(es) set forth below.
- ☐ by personally delivering the document(s) listed above to the person(s) at the address(es) set forth below.
- ☐ by placing the document(s) listed above in a sealed envelope(s) and consigning it to an express mail service for guaranteed delivery on the next business day following the date of consignment to the address(es) set forth below.
- ☐ by transmitting via email to the parties at the email addresses listed below:

Theodore J. Holt, Esq.
David R. Zarka, Esq.
Alissa S. Holt, Esq.
Hackard & Holt
11335 Gold Express Drive, Suite 105
Gold River, CA 95670

Tel: (916) 853-3000
Fax: (916) 853-3010

Attorneys for Plaintiff

Anthony G. Brazil, Esq.
Kanika D. Corley, Esq.
Morris Polich & Purdy, LLP
1055 West Seventh Street, 24th Floor
Los Angeles, CA 90017

Tel: (213) 891-9100
Fax: (213) 488-1178

Attorneys for Defendant
McKesson Corporation

1 Peter E. Schnaitman, Esq.
2 Tucker, Willis & West
3 1000 Wilshire Blvd., Suite 1800
4 Los Angeles, CA 90017-2475

5 Tel: (213) 430-3400
6 Fax: (213) 430-3409


7 Attorneys for Defendants
8 Pfizer, Inc.; Pharmacia Corporation and G. D. Searle LLC

Anthony G. Brazil, Esq.
Kanika D. Corley, Esq.
Claudine Horowitz, Esq.
Morris Polich & Purdy, LLP
1055 West Seventh Street, 24th Floor
Los Angeles, CA 90017

Tel: (213) 891-9100
Fax: (213) 488-1178

Attorneys for Defendant
Amerisourcebergen Drug Corporation

I declare under penalty of perjury under the laws of the State of California that the
above is true and correct. Executed on December 5, 2006, at Oakland, California.


Sandra A. Lasarte

REED SMITH LLP
A limited liability partnership formed in the State of Delaware